These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 17192328

  • 1. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A.
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [Abstract] [Full Text] [Related]

  • 2. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 3. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G.
    Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
    [Abstract] [Full Text] [Related]

  • 4. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID.
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [Abstract] [Full Text] [Related]

  • 5. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
    Svendsen M, Helgeland M, Tonstad S.
    J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
    [Abstract] [Full Text] [Related]

  • 6. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 7. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
    Madsen EL, Bruun JM, Skogstrand K, Hougaard DM, Christiansen T, Richelsen B.
    Metabolism; 2009 Jul; 58(7):946-53. PubMed ID: 19409578
    [Abstract] [Full Text] [Related]

  • 8. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ, Dias T, Chambel P, Carvalheiro M, Correia LG, Guerreiro L, Marques O, Medina JL, Nobre E, Nunes JS, Pereiraa MC, Polónia J, Portugal J, Raimundo A, Ruas A, da Silva PM, Vasconcelos C, Reis JL, Teles AG.
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [Abstract] [Full Text] [Related]

  • 9. Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial.
    Svendsen M, Rissanen A, Richelsen B, Rössner S, Hansson F, Tonstad S.
    Obesity (Silver Spring); 2008 Feb; 16(2):327-33. PubMed ID: 18239640
    [Abstract] [Full Text] [Related]

  • 10. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
    Anderson JW, Schwartz SM, Hauptman J, Boldrin M, Rossi M, Bansal V, Hale CA.
    Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
    Lacey LA, Wolf A, O'shea D, Erny S, Ruof J.
    Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
    [Abstract] [Full Text] [Related]

  • 12. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.
    MacLaughlin HL, Cook SA, Kariyawasam D, Roseke M, van Niekerk M, Macdougall IC.
    Am J Kidney Dis; 2010 Jan; 55(1):69-76. PubMed ID: 19926371
    [Abstract] [Full Text] [Related]

  • 13. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
    Tzotzas T, Samara M, Constantinidis T, Tziomalos K, Krassas G.
    Angiology; 2007 Jan; 58(1):26-33. PubMed ID: 17351155
    [Abstract] [Full Text] [Related]

  • 14. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E, Kolanowski J, Scheen A, Van Gaal L, ObelHyx Study Group.
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [Abstract] [Full Text] [Related]

  • 15. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
    Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA.
    Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM, Huang BY, Fanchiang JK, Chen CH.
    Chang Gung Med J; 2007 Jan; 30(6):538-46. PubMed ID: 18350737
    [Abstract] [Full Text] [Related]

  • 17. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
    Erdmann J, Lippl F, Klose G, Schusdziarra V.
    Aliment Pharmacol Ther; 2004 Jun 01; 19(11):1173-9. PubMed ID: 15153170
    [Abstract] [Full Text] [Related]

  • 18. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM.
    Obes Res; 2000 Sep 01; 8(6):431-7. PubMed ID: 11011909
    [Abstract] [Full Text] [Related]

  • 19. Effect of orlistat in obese patients with binge eating disorder.
    Golay A, Laurent-Jaccard A, Habicht F, Gachoud JP, Chabloz M, Kammer A, Schutz Y.
    Obes Res; 2005 Oct 01; 13(10):1701-8. PubMed ID: 16286517
    [Abstract] [Full Text] [Related]

  • 20. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
    Rowe R, Cowx M, Poole C, McEwan P, Morgan C, Walker M.
    Curr Med Res Opin; 2005 Nov 01; 21(11):1885-90. PubMed ID: 16307710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.